New perspectives in the renin-angiotensin-aldosterone system (RAAS) III: Endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Fagyas, Miklos ^a   Úri, Katalin ^a   Siket, Ivetta M ^a   Daragó, Andrea ^a   Boczán, Judit ^a   Bányai, Emese ^a   Édes, Istvan ^a   Papp, Zoltan ^a   Tóth, Attila ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; HUMAN SERUM ALBUMIN; IRBESARTAN; LOSARTAN; TELMISARTAN; TRIACYLGLYCEROL; UREA; URIC ACID; VALSARTAN; ALDOSTERONE; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SERUM ALBUMIN;

ADULT; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART RATE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; AGED; BLOOD; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; SERUM ALBUMIN;

EID: 84898619164     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093719     Document Type: Review

References (64)

1. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327: 669-677.
2. Corvol P, Michaud A, Soubrier F, Williams TA (1995) Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. J Hypertens Suppl 13: S3-10.
3. Bian B, Kelton CML, Guo JJ, Wigle PR (2010) ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008. J Manag Care Pharm 16: 671-679.
4. Fox KM (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782-788. (Pubitemid 37093919)
5. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardic (1996) Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. J Am Coll Cardiol 27: 337-344.
6. Group I-4 C (1995) ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative. Lancet 345: 669-685.
7. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, et al. (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303-310.
8. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, et al. (1995) Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 91: 2573-2581.
9. Luders S, Schrader J, Berger J, Unger T, Zidek W, et al. (2008) The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26: 1487-1496.
10. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, et al. (2002) Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 20: 2293-2300. (Pubitemid 35388249)
11. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, et al. (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941-1951. (Pubitemid 39447135)
12. Hoogwerf BJ, Young JB (2000) The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not. Cleve Clin J Med 67: 287-293.
13. Taylor J (2012) Joint societies CVD Prevention Guidelines launched in May 2012. Eur Heart J 33: 1539.
14. McMurray JJ V, Adamopoulos S, Anker SD, Auricchio A, Bohm M, et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. Eur Heart J 33: 1787-1847.
15. Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, et al. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevatio. Eur Heart J 32: 2999-3054.
16. Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clement D, et al. (2011) ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatm. Eur Heart J 32: 2851-2906.
17. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, et al. (2010) Guidelines on myocardial revascularization. Eur Heart J 31: 2501-2555.
18. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136.
19. Wald NJ, Law MR (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326: 1419.
20. Ferdinand KC (2003) Recommendations for the management of special populations: racial and ethnic populations. Am J Hypertens 16: 50S-54S. (Pubitemid 37449440)
21. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, et al. (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346. (Pubitemid 20370444)
22. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, et al. (1992) Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin Iconverting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51: 197-205.
23. Danilov S, Savoie F, Lenoir B, Jeunemaitre X, Azizi M, et al. (1996) Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies. J Hypertens 14: 719-727. (Pubitemid 26187406)
24. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, et al. (2006) Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 48: 914-920. (Pubitemid 44611005)
25. Fagyas M, Uri K, Manyine IS, Fulop GA, Csato V, et al. (2014) New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human. PLoS One. doi:10.1371/journal.pone.0087844.
26. Fagyas M, Uri K, Manyine IS, Darago A, Boczan J, et al. (2014) New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition. PLoS One. doi:10.1371/ journal.pone.0087843.
27. Beneteau B, Baudin B, Morgant G, Giboudeau J, Baumann FC (1986) Automated kinetic assay of angiotensin-converting enzyme in serum. Clin Chem 32: 884-886. (Pubitemid 17028376)
28. Rigat B, Hubert C, Corvol P, Soubrier F (1992) PCR detection of the insertion/ deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 20: 1433.
29. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, et al. (1995) A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 332: 706-711.
30. Klauser RJ, Robinson CJ, Marinkovic DV, Erdos EG (1979) Inhibition of human peptidyl dipeptidase (angiotensin I converting enzyme: kininase II) by human serum albumin and its fragments. Hypertension 1: 281-286.
31. Klauser RJ, Robinson CJ, Marinkovic DV, Erdos EG (1979) Inhibition of human peptidyl dipeptidase (angiotensin I converting enzyme: kininase II) by human serum albumin and its fragments. Hypertension 1: 281-286.
32. Lieberman J, Sastre A (1986) An angiotensin-converting enzyme (ACE) inhibitor in human serum. Increased sensitivity of the serum ACE assay for detecting active sarcoidosis. Chest 90: 869-875.
33. Brecher AS, Thevananther S, Wilson S (1996) Observation of high and low molecular weight inhibitors of angiotensin-converting enzyme in rat lung. Arch Int Pharmacodyn Ther 331: 301-312. (Pubitemid 27026457)
34. Wanasundara PKJPD, Ross ARS, Amarowicz R, Ambrose SJ, Pegg RB, et al. (2002) Peptides with angiotensin I-converting enzyme (ACE) inhibitory activity from defibrinated, hydrolyzed bovine plasma. J Agric Food Chem 50: 6981-6988. (Pubitemid 35332771)
35. Nakagomi K, Yamada R, Ebisu H, Sadakane Y, Akizawa T, et al. (2000) Isolation of Acein-2, a novel angiotensin-I-converting enzyme inhibitory peptide derived from a tryptic hydrolysate of human plasma. FEBS Lett 467: 235-238. (Pubitemid 30081741)
36. Nakagomi K, Fujimura A, Ebisu H, Sakai T, Sadakane Y, et al. (1998) Acein-1, a novel angiotensin-I-converting enzyme inhibitory peptide isolated from tryptic hydrolysate of human plasma. FEBS Lett 438: 255-257. (Pubitemid 28529284)
37. Davidson NC, Barr CS, Struthers AD (1996) C-type natriuretic peptide. An endogenous inhibitor of vascular angiotensin-converting enzyme activity. Circulation 93: 1155-1159.
38. Ikemoto F, Song GB, Tominaga M, Yamamoto K (1989) Endogenous inhibitor of angiotensin converting enzyme in the rat heart. Biochem Biophys Res Commun 159: 1093-1099. (Pubitemid 19101094)
39. Ryan JW, Martin LC, Chung A, Pena GA (1979) Mammalian inhibitors of angiotensin converting enzyme (kininase II). Adv Exp Med Biol 120B: 599-606.
40. Guang C, Phillips RD (2009) Plant food-derived Angiotensin I converting enzyme inhibitory peptides. J Agric Food Chem 57: 5113-5120.
41. Leon-Ruiz V, Gonzalez-Porto AV, Al-Habsi N, Vera S, San Andres MP, et al. (2013) Antioxidant, antibacterial and ACE-inhibitory activity of four monofloral honeys in relation to their chemical composition. Food Funct.
42. Rao S, Sun J, Liu Y, Zeng H, Su Y, et al. (2012) ACE inhibitory peptides and antioxidant peptides derived from in vitro digestion hydrolysate of hen egg white lysozyme. Food Chem 135: 1245-1252.
43. Tauzin J, Miclo L, Gaillard JL (2002) Angiotensin-I-converting enzyme inhibitory peptides from tryptic hydrolysate of bovine alphaS2-casein. FEBS Lett 531: 369-374. (Pubitemid 35341226)
44. Rogerson FM, Livett BG, Scanlon D, Mendelsohn FA (1989) Inhibition of angiotensin converting enzyme by N-terminal fragments of substance P. Neuropeptides 14: 213-217. (Pubitemid 20032937)
45. Snyder RA, Wintroub BU (1986) Inhibition of angiotensin-converting enzyme by des-Leu10-angiotensin I: a potential mechanism of endogenous angiotensinconverting enzyme regulation. Biochim Biophys Acta 871: 1-5. (Pubitemid 16064518)
46. Alhenc-Gelas F, Weare JA, Johnson RL, Erdos EG (1983) Measurement of human converting enzyme level by direct radioimmunoassay. J Lab Clin Med 101: 83-96. (Pubitemid 13170298)
47. Stevens J, Danilov S, Fanburg BL, Lanzillo JJ (1990) A sensitive two-site sandwich enzyme immunoassay for human angiotensin converting enzyme utilizing monoclonal antibodies. J Immunol Methods 132: 263-273. (Pubitemid 20281886)
48. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A (2000) ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol 20: 484-492. (Pubitemid 30086107)
49. Van Dijk MA, Kroon I, Kamper AM, Boomsma F, Danser AH, et al. (2000) The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm. J Cardiovasc Pharmacol 35: 484-490. (Pubitemid 30127198)
50. Danser AHJ, Batenburg WW, van den Meiracker AH, Danilov SM (2007) ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition? Pharmacol Ther 113: 607-618. (Pubitemid 46365959)
51. Muller BR (2002) Analysis of serum angiotensin-converting enzyme. Ann Clin Biochem 39: 436-443. (Pubitemid 34983438)
52. Kramers C, Danilov SM, Deinum J, Balyasnikova IV, Scharenborg N, et al. (2001) Point mutation in the stalk of angiotensin-converting enzyme causes a dramatic increase in serum angiotensin-converting enzyme but no cardiovascular disease. Circulation 104: 1236-1240. (Pubitemid 32848111)
53. Nesterovitch AB, Hogarth KD, Adarichev VA, Vinokour EI, Schwartz DE, et al. (2009) Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE. PLoS One 4: e8282.
54. Semmler A, Stein RW, Caplan L, Danilov SM, Klockgether T, et al. (2006) Hereditary hyper-ACE-emia due to the Pro1199Leu mutation of somatic ACE as a potential pitfall in diagnosis: a first family outside Europe. Clin Chem Lab Med 44: 1088-1089. (Pubitemid 44370927)
55. Eyries M, Michaud A, Deinum J, Agrapart M, Chomilier J, et al. (2001) Increased shedding of angiotensin-converting enzyme by a mutation identified in the stalk region. J Biol Chem 276: 5525-5532.
56. Linnebank M, Kesper K, Jeub M, Urbach H, Wullner U, et al. (2003) Hereditary elevation of angiotensin converting enzyme suggesting neurosarcoidosis. Neurology 61: 1819-1820. (Pubitemid 38020844)
57. Persu A, Lambert M, Deinum J, Cossu M, de Visscher N, et al. (2013) A novel splice-site mutation in angiotensin I-converting enzyme (ACE) gene, c.3691+ 1G.A (IVS25+1G.A), causes a dramatic increase in circulating ace through deletion of the transmembrane anchor. PLoS One 8: e59537.
58. Thevananther S, Brecher AS (1999) Isolation of angiotensin converting enzyme (ACE) binding protein from human serum with an ACE affinity column. Can J Physiol Pharmacol 77: 216-223. (Pubitemid 29342845)
59. Nakagomi K, Ebisu H, Sadakane Y, Fujii N, Akizawa T, et al. (2000) Properties and human origin of two angiotensin-I-converting enzyme inhibitory peptides isolated from a tryptic hydrolysate of human serum albumin. Biol Pharm Bull 23: 879-883. (Pubitemid 30484389)
60. Uri K, Fagyas M, Manyine IS, Kertesz A, Csanadi Z, et al. (2014) New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: Circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. PLoS One.
61. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, et al. (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243.
62. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RAS, et al. (2011) Angiotensin-converting enzyme 2 activation protects against hypertensioninduced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96: 287-294.
63. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, et al. (2010) Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59: 529-538.
64. Howard G, Downward G, Bowie D (2001) Human serum albumin induced hypotension in the postoperative phase of cardiac surgery. Anaesth Intensive Care 29: 591-594. (Pubitemid 33138612)